Transgene (XPAR:TNG) Beginning Cash Position : €3.72 Mil (As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Transgene Beginning Cash Position?

Transgene's Beginning Cash Position for the quarter that ended in Dec. 2023 was €3.72 Mil.

Transgene's quarterly Beginning Cash Position declined from Dec. 2022 (€7.14 Mil) to Jun. 2023 (€4.40 Mil) and declined from Jun. 2023 (€4.40 Mil) to Dec. 2023 (€3.72 Mil).

Transgene's annual Beginning Cash Position increased from Dec. 2021 (€5.28 Mil) to Dec. 2022 (€5.91 Mil) but then declined from Dec. 2022 (€5.91 Mil) to Dec. 2023 (€4.40 Mil).

Transgene Beginning Cash Position Historical Data

The historical data trend for Transgene's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Beginning Cash Position Chart

Transgene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

1.89

1.34

5.28

5.91

4.40

Transgene Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Beginning Cash Position	Get a 7-Day Free Trial															11.49	5.91	7.14	4.40	3.72

Transgene Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Transgene Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Transgene's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Transgene (XPAR:TNG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

TGNA:Germany

Address

400 Boulevard Gonthier d’Andernach, Parc d’Innovation - CS80166, Illkirch-Graffenstaden, FRA, 67400

Website

https://www.transgene.fr

Transgene SA is a biotechnology company. It is involved in the business of discovering and focusing immune-targeted therapies for the treatment of cancer and infectious diseases. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products.

Transgene (XPAR:TNG) Headlines

No Headlines